Browse the evidence

Dispensing rates for GLP-1 RAs are lower in patients aged 65+ compared to those aged 18-64, particularly for AOM indications.

Older adults (65+) are less likely to fill GLP-1 RA prescriptions for weight loss compared to younger adults, largely due to Medicare not covering these medications. If you are 65 or older, discuss alternative coverage options or patient assistance programs with your healthcare provider.

Triple agonists targeting GLP-1, GIP, and Glucagon receptors improve energy expenditure and restore body weight in diet-induced obesity models more effectively than dual or mono-agonists.

Triple hormone agonists (GLP-1/GIP/Glucagon) are in development and show promise in animal studies for boosting energy expenditure and weight loss beyond what dual agonists achieve. They are not yet standard clinical care.

GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.

The addition of GIP receptor activation in dual agonists may help improve insulin sensitivity through metabolic pathways in fat tissue, independent of just losing weight.

Reducing saturated fat intake has little or no effect on all-cause mortality, cardiovascular mortality, or cancer deaths in adults.

While reducing saturated fat is excellent for preventing heart attacks and strokes, you should not expect it to drastically extend your lifespan on its own. Focus on the quality of life and prevention of non-fatal cardiovascular events as the primary benefit.

Adjunctive liraglutide 1.8 mg for 6 months following laparoscopic adjustable gastric banding (LAGB) provides no significant additional improvement in HbA1c or body weight compared to LAGB alone, and cessation of therapy leads to significant weight regain and worsening glycemic control relative to placebo.

If you have had a gastric band and are considering adding Liraglutide (Victoza) for 6 months, current evidence suggests it will not provide extra weight loss or blood sugar benefits during that time, and you may regain more weight after stopping it compared to not taking it. This does not rule out other GLP-1 drugs (like Semaglutide) or longer durations, but for this specific protocol, it is not recommended.

Semaglutide therapy in older adults with type 2 diabetes accelerates muscle mass loss and functional decline, with higher doses and lower baseline muscle mass predicting greater loss.

If you are taking Semaglutide and are over 65 with diabetes, monitor your muscle strength. The medication can cause muscle loss, especially at higher doses. To counter this, focus on resistance training and adequate protein intake, and discuss dose adjustments with your doctor if you notice weakness.

Social media platforms (Instagram, TikTok) misrepresent semaglutide by promoting off-label weight loss use while omitting common adverse effects like gastrointestinal disorders, leading to unreflected medication use and supply shortages for indicated patients.

If you are considering semaglutide for weight loss, understand that it is a prescription medication with significant side effects, primarily gastrointestinal issues. Social media often omits these risks. Consult a healthcare provider to ensure it is appropriate for you and to avoid contributing to shortages for diabetic patients.

Enhancing insulin signaling specifically in adipose tissue improves obesity-related metabolic disorders by promoting healthy fat expansion and preventing ectopic fat accumulation, whereas enhancing insulin signaling in the liver exacerbates metabolic dysfunction.

Treating obesity-related metabolic issues requires targeting the right tissue. Simply boosting insulin systemically can be harmful, particularly to the liver. Future therapies must distinguish between adipose tissue (where boosting insulin helps store fat safely) and the liver (where boosting insulin worsens fat accumulation). Current clinical focus remains on lifestyle changes and existing drugs that improve sensitivity, but the research highlights the need for tissue-specific drugs.

Tirzepatide treatment in high-fat diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) mice significantly reduces hepatic lipid accumulation and liver damage by downregulating fatty acid uptake proteins (Cd36, Fabp2/4) and upregulating cholesterol efflux regulators (Hnf4a, Abcg5, Abcg8).

For individuals with fatty liver disease, tirzepatide (a dual GIP/GLP-1 agonist) has been shown in preclinical models to reduce liver fat and inflammation. It works by decreasing fatty acid uptake and increasing cholesterol excretion. While promising, these results are from mice, and human clinical data is needed to confirm efficacy and safety for liver health specifically.

Current standard-of-care structured lifestyle modification (500 kcal deficit + 150 min activity) added to obesity pharmacotherapy lacks evidence of improving drug response and may act as a barrier to care by reinforcing stigma.

If you are starting obesity medication, you do not need to complete a mandatory lifestyle program to access or benefit from it. Current evidence does not show that mandatory calorie counting and exercise improve drug results. Focus on your health and well-being; if you choose to make lifestyle changes, do so for yourself, not as a requirement for your medication.

Pharmacological activation of brown adipose tissue (BAT) and induction of 'browning' in white adipose tissue (WAT) via agents such as β3-adrenergic receptor agonists, thyroid receptor agonists, and GLP-1-based multi-agonists enhances energy expenditure and improves metabolic parameters, offering a potential therapeutic avenue for obesity management.

This research suggests that certain medications (like GLP-1 agonists or specific receptor agonists) may help manage obesity not just by suppressing appetite, but by actively turning on your body's internal heating system (brown fat). This process burns energy as heat, which can improve blood sugar and lipid levels. While this might not always lead to massive weight loss on its own, it addresses the metabolic slowdown that often hinders long-term weight management.

Obesity-associated low-grade inflammation and adipose tissue dysfunction can induce resistance to β3-adrenergic receptor agonists (like CL316243) by suppressing β3-AR expression via the EPAC/RAP2A signaling pathway, thereby blunting thermogenic efficacy.

If you have obesity-related inflammation, standard fat-burning medications that target specific receptors (like β3-agonists) might be less effective because your body's inflammatory state can block these receptors. This highlights why some people don't respond to certain treatments and why newer drugs with different mechanisms might be needed.

Tirzepatide demonstrates potential kidney-protective effects by slowing the decline in eGFR and reducing urinary albumin-to-creatinine ratio (UACR) compared to insulin glargine.

While not yet a primary indication, early data suggests tirzepatide may help protect kidney function in T2D patients, potentially slowing kidney disease progression compared to insulin. This benefit is observed even in patients already taking other kidney-protective medications.

SGLT2 inhibitors reduce epicardial fat volume independently of significant weight loss, suggesting a direct lipolytic effect on epicardial tissue.

SGLT2 inhibitors are a key pharmacological option for HFpEF patients. They reduce epicardial fat directly, which may improve heart mechanics and reduce hospitalizations. Discuss with your doctor if SGLT2 inhibitors are appropriate for your condition.

Patients with active psychiatric disorders, particularly depression, may exhibit lower response rates to semaglutide and are at risk of weight gain during treatment.

If you have active depression or other psychiatric conditions, monitor your weight closely when starting semaglutide, as some patients may not lose weight or may even gain weight.

BGM0504, a GLP-1R/GIPR dual agonist with optimized acylation, demonstrates superior glycemic control, weight loss, and liver health improvements compared to Tirzepatide in diabetic and NASH mouse models.

BGM0504 is an experimental dual-agonist peptide designed to treat diabetes and obesity more effectively than existing drugs like Tirzepatide. In animal studies, it lowered blood sugar and body weight with fewer side effects on liver health. It is not yet available for human use.

Non-surgical weight management programs (WMPs) for adults with severe obesity (BMI ≥ 35 kg/m2) lack a clear consensus on cost-effectiveness, largely due to short-term study durations and heterogeneous definitions of usual care.

For individuals with severe obesity (BMI ≥ 35), non-surgical weight management programs exist but their cost-effectiveness is not clearly established. Most studies are short-term and do not capture long-term health outcomes. It is important to consult with healthcare providers to understand the potential benefits and costs of various non-surgical options, including lifestyle changes, VLCDs, and pharmacotherapy, as the evidence is heterogeneous.

Quercetin supplementation has no significant effect on Interleukin-6 (IL-6) concentrations after exercise.

Do not expect quercetin to significantly lower IL-6 levels post-exercise based on current meta-analytic data.

Adherence to an ultra low-fat diet (ULF) leads to a compensatory increase in refined grain intake, which may undermine the cardioprotective potential of fat restriction.

If you choose a low-fat diet, be aware that your body may crave carbohydrates. You must actively replace the calories from fat with vegetables and whole foods, not refined grains or sugars. If you find yourself eating more bread or pasta to feel full, your heart health benefits may be negated by the increased refined carbohydrate intake.

Soluble GPNMB (sGPNMB) promotes lipogenesis in white adipose tissue by activating SREBP1c via CD44 binding, thereby acting as a risk factor for obesity progression.

This research highlights that obesity involves complex signaling where soluble proteins released by fat cells can drive further fat storage. While not a direct lifestyle intervention, understanding this mechanism underscores why reducing adiposity (via caloric deficit and exercise) is crucial, as it reduces the source of these pro-lipogenic signals.

Membrane-bound GPNMB on anti-inflammatory macrophages reduces oxidative stress, lipid accumulation, and fibrosis in the liver by interacting with calnexin on Kupffer and stellate cells.

This finding suggests that maintaining healthy macrophage function in fat tissue may have downstream benefits for liver health, potentially reducing the risk of fatty liver disease associated with obesity.

Obesogenic food environments disproportionately increase obesity risk for women compared to men due to biological factors (hormonal modulation of taste/storage), gendered marketing targeting women, and structural burdens (unpaid labor/food security) that limit healthy food access.

Recognize that obesity is not just a personal failure but a result of an environment designed to promote weight gain, which affects women differently due to biological and social factors. Focus on structural changes (policy, food environment) rather than just individual willpower. For women, be aware that marketing and household responsibilities may create unique barriers to healthy eating that require specific, gender-responsive solutions.

Semaglutide use is associated with a significantly higher reporting odds ratio for vision impairment and retinopathy compared to other GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, metformin, phentermine, and orlistat.

If you are taking semaglutide, be aware that there is a statistical signal for increased vision impairment reports in post-market data compared to other diabetes or weight loss drugs. This does not mean everyone will experience this, but it warrants vigilance. Ensure you have regular ophthalmological check-ups, especially if you have pre-existing diabetic retinopathy or rapid glycemic changes, and report any visual disturbances to your provider immediately.

Intravenous amino acid infusion improves muscle protein synthesis and reduces perioperative blood loss in total joint arthroplasty patients.

If your surgical team recommends intravenous amino acids during your joint replacement, it may help preserve muscle protein and reduce blood loss. This is a specific medical intervention that complements your surgery, not a substitute for post-operative nutrition.